

PRECEPTORSHIP PROGRAMME

Prostate Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

SINGAPORE

21-22 NOVEMBER 2018

Co-Chairs Ravindran Kanesvaran, SG
Nicolas Mottet, FR

ESMO PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Singapore
21-22 November 2018

CO-CHAIRS:

Ravindran Kanesvaran, Singapore
Nicolas Mottet, France

SPEAKERS:

Melvin L. K. Chua, Singapore
Ronald de Wit, Netherlands
Shigeo Horie, Japan
Jin Wei Kwek, Singapore
Lui Shiong Lee, Singapore
Tanujaa Rajasekaran, Singapore
Puay Hoon Tan, Singapore

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 21 November 2018

09:00-09:15 15'	Opening and welcome	
15'	Welcome from ESMO - Objectives and scientific introduction	Ravindran Kanesvaran, SG Nicolas Mottet, FR
09:15-10:30 75'	SESSION 1 Screening, diagnosis and staging	Chair: Puay Hoon Tan, SG
20'	PSA screening and diagnosis	Shigeo Horie, JP
20'	Diagnosis and impact of pathology on prognosis	Puay Hoon Tan, SG
20'	Latest in imaging and staging classification	Jin Wei Kwek, SG
15'	Discussion	Faculty
10:30-11:00	Coffee break	
11:00-12:30 90'	SESSION 2 Localized prostate cancer	Chair: Nicolas Mottet, FR
20'	Role of radiotherapy	Melvin L. K. Chua, SG
20'	Role of surgery	Nicolas Mottet, FR
20'	Active surveillance	Lui Shiong Lee, SG
30'	Participants clinical case discussion (2x15')	Faculty
12:30-13:30	Lunch	
13:30-15:15 105'	SESSION 3 Advanced prostate cancer	Chair: Shigeo Horie, JP
15'	Presentation with lymphadenopathy	Melvin L. K. Chua, SG
20'	Value and role of PSA as a tumour marker of response / relapse	Shigeo Horie, JP
10'	Managing urinary obstruction	Lui Shiong Lee, SG
<u>Debate:</u> For a locally advanced lesion, is the preferred local treatment (combined with a systemic one) EBRT or surgery?		
10'	Arguments for EBRT	Melvin L. K. Chua, SG
10'	Arguments for surgery	Shigeo Horie, JP
10'	General discussion	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
15:15-15:45	Coffee break	
15:45-17:15 90'	SESSION 4 Initial systemic therapy	Chair: Tanujaa Rajasekaran, SG
20'	Current standard of care for newly diagnosed M1 disease	Nicolas Mottet, FR
20'	Evidence for M1 relapsing after local treatment	Tanujaa Rajasekaran, SG
20'	How to choose?	Ravindran Kanesvaran, SG
30'	Participants clinical case discussion (2x15')	Faculty
20:00	Dinner	

Thursday, 22 November 2018

08:30-10:00 90'	SESSION 5 Current treatment in Castration Resistant Prostate Cancer (CRPC)	Chair: Ravindran Kanesvaran, SG
20'	M0 CRPC: Where are we in 2018?	Ravindran Kanesvaran, SG
20'	M1 CRPC: Available data regarding trials	Tanujaa Rajasekaran, SG
20'	M1 CRPC: Choosing and sequencing drugs in practice	Ronald de Wit, NL
30'	Participants clinical case discussion (2x15')	Faculty
10:00-10:30	Coffee break	
10:30-12:00 90'	SESSION 6 CRPC: Bone modulation and the future	Chair: Ronald de Wit, NL
20'	Bone targeting (bisphosphonates, RANK ligands and radioisotopes)	Tanujaa Rajasekaran, SG
25'	New drug targets (including PSMA targeted agents)	Ronald de Wit, NL
45'	Participants clinical case discussion (3x15')	Faculty
12:00-12:15 15'	Conclusion and farewell	Ravindran Kanesvaran, SG Nicolas Mottet, FR
12:15-13:15	Lunch	

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion